AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06158633
Drug: Prevora
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prevora Stage 1, a topical, intra-oral solution of chlorhexidine acetate 100mg/ml followed immediately by Prevora Stage 2 which is a topical solution of polymethylmethacrylate. Prevora Stage 1 and Prevora Stage 2 are applied topically using a small brush and sequentially to the teeth and gum line of the patient/participant.~All subjects will receive at total 4 applications of Prevora 1 and 2. One on Day 1, 14 days, 3 months and 4 months.
Trial: NCT05148884
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be matching tablets (identical weight, shape and color) without NLX-112.
Trial: NCT05278156
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is to be oral administered. Each patient is to take 4 capsules of placebo daily.
Trial: NCT06147232
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT05619965
Drug: sedative
RxNorm normalized name: Sedative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexmedetomidine 1 mic/kg IV over 10 minutes then 0.4 mic/kg/h continuous IV infusion
Trial: NCT05152186
Drug: Topical Solution
RxNorm normalized name: Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration
Trial: NCT05152186
Drug: Topical Foam
RxNorm normalized name: Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration
Trial: NCT05424393
Drug: csDMARDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: csDMARDs include methotrexate, sulfasalazine, hydroxychloroquine and leflunomide The use of csDMARDs complies with clinical routine practice and treatment strategy of treat-to-target.
Trial: NCT05981066
Drug: Neoantigen vaccine, I.M injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a fixed applicable dose of ABOR2014(IPM511) administered.
Trial: NCT05684640
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0mg, BID
Trial: NCT05319860
Drug: Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care for CINV includes anti-nausea medication as needed after chemotherapy regimen given for up to 12 weeks.
Trial: NCT05319860
Drug: Aromatherapy Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An aromatherapy inhaler provided for use as needed after chemotherapy regimen given for up to 12 weeks. One normal inhale is equal to one dose of aromatherapy. Participants can use the aromatherapy as often as needed.
Trial: NCT06290128
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution Route of administration: IV Infusion
Trial: NCT06290128
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution Route of administration: SC Injection
Trial: NCT06667960
Drug: JK06
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Biparatopic anti-5T4 antibody
Trial: NCT05023031
Drug: NVP-2102-R
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet formulation for oral administration, single dose of NVP-2102-R at Day 1
Trial: NCT04560179
Drug: Tobramycin solution for inhalation 78mg dose
RxNorm normalized name: Tobramycin Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled tobramycin - 78mg administered every 12 hours for 14 days.
Trial: NCT04560179
Drug: Tobramycin solution for inhalation 150mg dose
RxNorm normalized name: Tobramycin Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled tobramycin - 150mg administered every 12 hours for 14 days.
Trial: NCT04560179
Drug: Tobramycin solution for inhalation 216mg dose
RxNorm normalized name: Tobramycin Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled tobramycin - 216mg administered every 12 hours for 14 days.
Trial: NCT04560179
Drug: Tobramycin solution for inhalation 300mg dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled tobramycin - 300mg administered every 12 hours for 14 days.
Trial: NCT05087030
Drug: RGB-14-P
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive RGB-14-P into the thigh, abdomen, or upper arm as per the arm assigned.
Trial: NCT05087030
Drug: Prolia®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Prolia® into the thigh, abdomen, or upper arm as per the arm assigned.
Trial: NCT06670963
Drug: Iron
RxNorm normalized name: Iron
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron derisomaltose 0.2g IV if reticulocyte hemoglobin equivalent \<29.3 pg (lower limit for the local laboratory reference range for reticulocyte hemoglobin equivalent)
Trial: NCT06670963
Drug: 0.9 % NaCl
RxNorm normalized name: dextrose 10 %-0.9 % NaCl MISCELL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume of 0.9% NaCl identical as volume of medications used in experimental arm
Trial: NCT05205161
Drug: AZD0466
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive treatment with the investigational product AZD0466 via intravenous infusion.
Trial: NCT04643769
Drug: ORIN1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet - ORIN1001
Trial: NCT04643769
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet - placebo
Trial: NCT06234995
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will take levodopa in dosages prescribed by their care provider. Patients will be instructed to not take their regularly prescribed PD medications for 12 hours prior to the study assessment, as is typical for clinical evaluations in patients with PD. Participants will be tested in both levodopa-off (after 12 hours of not having medication) and levodopa-on states.
Trial: NCT06063473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
Trial: NCT06063473
Drug: AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
Trial: NCT05535166
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Route of administration: Intravenously (IV)
Trial: NCT05535166
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Route of administration: Intravenously (IV)
Trial: NCT06612268
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching Etavopivat will be administered orally.
Trial: NCT02934282
Drug: HBOC-201
RxNorm normalized name: Hib (HbOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin Based Oxygen Carrier (HBOC)
Trial: NCT05100706
Drug: Sham continuous adductor canal block (ShACB).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% infusion through adductor canal catheter
Trial: NCT05870865
Drug: ASN008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASN008 topical gel applied twice daily.
Trial: NCT04026568
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm
Trial: NCT06422182
Drug: Bupivacain 25% (Erector Spinae Plane Block)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received ultrasound guided bilateral single shot erector spinae pane block (ESPB) at Th10 level with 20 mL 0.25% bupivacaine after the end of surgery.
Trial: NCT05292755
Drug: Preservative-free, CMC-free Artificial Tears (control)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A pack of 21 vials of artificial tears containing 0.4% polyethylene glycol 400 and 0.3% propylene glycol will be given to subjects in the control group.
Trial: NCT05068856
Drug: HRS2543
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-escalation part For the dose-escalation study, five dose cohorts (25 mg , 75 mg , 150 mg , 300 mg , and 450 mg ) of HRS2543 are initially set.~Dose-expansion part After the completion of dose-escalation study, the dose-expansion study will be carried out at the recommended dose level by the SMC.
Trial: NCT04708587
Drug: dual anti-platelet therapy at least 6 months
RxNorm normalized name: omega-3 acid ethyl esters (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients enrolled in dual antiplatelets at least 6 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for at least 6 months after randomization. Clopidogrel or prasugrel should be maintained after 6 months.
Trial: NCT04708587
Drug: dual anti-platelet therapy 3months or less
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient enrolled in the dual antiplatelet therapy less than 3 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for less than 3 months after randomization. After 3 months clopidogrel or prasugrel should be maintained.
Trial: NCT05189444
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5g bid
Trial: NCT05733455
Drug: Placebo (microcrystalline cellulose), 2 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will ingest two capsules filled with microcrystalline cellulose at 23:00, along with a saltine cracker.
Trial: NCT05642377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral administration
Trial: NCT05642377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily oral administration
Trial: NCT04733820
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Paclitaxel or docetaxel + Cisplatin or carboplatin Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
Trial: NCT04052139
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In week 1, participants will take 1 placebo capsule once daily. In week 2, participants will take 1 placebo capsule three times per day. In weeks 3 through 7, 2 placebo capsules three times per day. In week 8, in days 1-4 participants will take 2 placebo capsules three times per day; in days 5-7, participants will take 1 placebo capsule three times per day. The placebo medications will be composed of lactose and will not contain active ingredients.
Trial: NCT06162455
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen-air mixture without NO after extubation after surgery for 5 days 2 times a day for 30 min
Trial: NCT06162455
Drug: 200- ppm NO
RxNorm normalized name: caffeine 200 MG [No Doz]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO will be supplemented at 200-ppm concentration after surgery for 5 days 2 times a day for 30 min
Trial: NCT04673383
Drug: SPL026
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous solution
Trial: NCT04673383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPL026-matched placebo
Trial: NCT00006187
Drug: Investigational drug
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR DEMENTIA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06551623
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin tablets 0.5 g
Trial: NCT05122130
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The donor site will be dressed with melatonin loaded gelatin sponge
Trial: NCT06090071
Drug: Phyto A+ Brightening Treatment
RxNorm normalized name: phytol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phyto A+ Brightening Treatment is a serum comprised of a soothing botanical blend matched with a keratolytic (3% azeleic acid), 2.5% niacinamide, a brightening compound (2 % α-arbutin), and botanical extracts
Trial: NCT05177796
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05177796
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05995704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to apraglutide
Trial: NCT05995704
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen mixed with a liquid meal
Trial: NCT05013437
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg once orally within 30 minutes before Evomela
Trial: NCT06386328
Drug: CKD-378, QD, PO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD-378, QD, PO
Trial: NCT06548815
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending single doses - 4 dose levels.
Trial: NCT05252598
Drug: Inonotus Obliquus Whole Extract
RxNorm normalized name: Inonotus obliquus whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg encapsulated chaga mushroom
Trial: NCT05011396
Drug: Placebo Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray delivered 20 minutes before the public speaking stressor
Trial: NCT05666089
Drug: Calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intracanal medication of calcium hydroxide paste (metapaste)
Trial: NCT05896007
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3.5 g/m\^2 ivgtt, D1 of each 28-day cycle
Trial: NCT06399783
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group of patients will be treated by topical application of simvastatin cubosomal nanoparticled twice daily for 6 months, while another group will be treated by fractional CO2 laser for 6 sessions sessions each will be followed immediately by topical application of topical simvastatin.
Trial: NCT06226402
Drug: Hypertonic saline 3% nebulizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive the standard pharmacotherapy + hypertonic saline 3% (5ml) nebulizer /8hr.
Trial: NCT06226402
Drug: Intravenous hypertonic saline 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive the standard pharmacotherapy + hypertonic saline 3% intravenous over 24 hours to maintain plasma Na level between 145-150 mEq/L.
Trial: NCT06326944
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
Trial: NCT06326944
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will be given paracetamol (15 mg /kg/8 hrs ).
Trial: NCT06294600
Drug: Clarithromycin 500mg
RxNorm normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets of 500mg of clarithromycin
Trial: NCT04954365
Drug: Rescue Post-Operative Nausea and Vomiting (PONV) treatment according to the standard of care (SOC)
RxNorm normalized name: Pepto Nausea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue Post-Operative Nausea and Vomiting (PONV) treatment
Trial: NCT05047523
Drug: ALXN1840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an oral tablet.
Trial: NCT05047523
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depending on the site/region, participants randomized to receive Standard of Care treatment will receive trientine, penicillamine, zinc, or a combination of these medicines, administered according to standard regimens.
Trial: NCT04918121
Drug: Yutiq 0.18 MG Drug Implant
RxNorm normalized name: Yutiq 0.18 MG Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a sustained-release steroid insert (Yutiq)
Trial: NCT04397484
Drug: 2% Xylocaine with adrenaline 1:200,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).
Trial: NCT05637255
Drug: SYL1801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in the eligible eye
Trial: NCT04815603
Drug: BGE-117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Treatment
Trial: NCT05318521
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 800mg ibuprofen sustained-release tablet is the same as the next generation of ibuprofen sustained-release tablets developed by foreign pharmaceutical companies, but does not contain a placebo that the active ingredient of ibuprofen
Trial: NCT05318521
Drug: Ibuprofen modified release tablet 800 mg
RxNorm normalized name: ibuprofen Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication: ibuprofen modified sustained release tablets 800 mg Ibuprofen sustained Release Tablet 800mg is a new generation of ibuprofen developed by overseas pharmaceutical companies. It works fast and lasts for up to 12 hours. The dosing regimen was twice daily, 12 hours apart. Ibuprofen :2-\[4-(2-methylpropyl) phenyl\] propionic acid, nonselective nonsteroidal anti-inflammatory drug (NSAID).
Trial: NCT05816681
Drug: DWJ1230
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daewoong Pharmaceutical
Trial: NCT05816681
Drug: DWB2001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daewoong Bio
Trial: NCT06266221
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo
Trial: NCT06266221
Drug: IV Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV placebo
Trial: NCT06437223
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 40mg, Two tablets per day
Trial: NCT04970329
Drug: Polyethylene Glycol 400 0.4%-Propylene Glycol 0.3%. and Dextran 0.1%Hypromellose 0.3%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs will be given to two group and third group will kept on placebo.
Trial: NCT06615674
Drug: Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first group is the Dapagliflozin group, which will get Dapagliflozin 10mg once a day every morning for 14 days. And the second group will have placebo for 14 days.
Trial: NCT04791579
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill
Trial: NCT06021678
Drug: EX103 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT00889096
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
Trial: NCT05281276
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the run-in period, the patients will take a single dose of celecoxib on Day 1. In a treatment cycle, the dosing schedule is one capsule(200 mg) daily.
Trial: NCT06667453
Drug: PGN-EDODM1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous (IV) infusion
Trial: NCT06349980
Drug: HLX53 (1000mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX53 will be administered by IV infusion at a fixed dose of 1000 mg on Day 1 of each 21-day cycle.
Trial: NCT06349980
Drug: HLX53 (2000mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLX53 will be administered by IV infusion at a fixed dose of 2000 mg on Day 1 of each 21-day cycle.
Trial: NCT05841940
Drug: [14C]HLX208
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbon-14 labeled HLX208
Trial: NCT06329050
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Placebo tablets
Trial: NCT01931514
Drug: Singulair® (Montelukast Sodium) Chewable Tablets 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06607185
Drug: LY4066434.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.